Bruker Corporation (BRKR) Stock Analysis
Healthcare · Medical Devices · NasdaqGS
Bruker Corporation (BRKR) posted $3.44B in revenue for fiscal 2025 (up 2.1% year over year), with a net loss of $22.50M, and has compounded revenue about 11.6%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Bruker Corporation
Bruker Corporation has grown revenue from $1.61B to $3.44B over the last 10 fiscal years, compounding about 11.6% a year. The most recent year was up 2.1%, so growth has cooled from its longer-run pace.
Net margin sits at -0.7%, down 4.1 points year over year on a 45.9% gross margin. It carries about $1.87B of total debt.
At today's valuation the market is pricing in roughly 39.6% annual free-cash-flow growth — versus the -28.7% it actually delivered over the last five years, so the price already assumes a step-up from the recent record. The one thing worth a second look in the filings is heavy debt load.
Synthesised from Bruker Corporation's SEC filings — descriptive, not advice. Ask the analyst your own question →
Bruker Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.61B | $1.77B | $1.90B | $2.07B | $1.99B | $2.42B | $2.53B | $2.96B | $3.37B | $3.44B |
| Gross profit | $745.30M | $816.00M | $900.00M | $995.30M | $939.80M | $1.21B | $1.31B | $1.51B | $1.65B | $1.58B |
| Net income | $153.60M | $78.60M | $179.70M | $197.20M | $157.80M | $277.10M | $296.60M | $427.20M | $113.10M | $-22.50M |
| Net margin | 9.5% | 4.5% | 9.5% | 9.5% | 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.7% |
Source: Bruker Corporation SEC filings (10-K). 17 years of history available in the interactive view.
Bruker Corporation: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $1869.1M is 13.9× last year's operating cash flow — it would take years of cash flow to clear.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -0.7%).
What growth is priced into BRKR stock?
At today's market cap of $8.41B, Bruker Corporation is priced for free-cash-flow growth of about 39.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $43.30M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -28.7%/yr over the last five fiscal years and revenue 11.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Bruker Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BRKR in your portfolio →
Bruker Corporation financial history by metric
Compare Bruker Corporation with peers
About Bruker Corporation
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
Bruker Corporation — frequently asked questions
What is Bruker Corporation's revenue?
Bruker Corporation (BRKR) reported revenue of $3.44B for fiscal year 2025, up 2.1% from the prior year, according to its SEC filings.
Is Bruker Corporation profitable?
No — BRKR reported a net loss of $-22.50M in fiscal 2025.
What is BRKR's P/E ratio?
Bruker Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Bruker Corporation growing?
BRKR's revenue grew at roughly 11.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bruker Corporation have?
As of fiscal year 2025, BRKR carried roughly $1.87B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bruker Corporation's gross margin?
BRKR's gross margin was 45.9% in fiscal 2025 — gross profit of $1.58B on revenue of $3.44B.
What is Bruker Corporation's market cap?
Bruker Corporation (BRKR) has a market capitalization of about $8.41B, based on the latest data in our nightly-refreshed cache.
When does Bruker Corporation's fiscal year end?
BRKR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BRKR stock?
At today's market cap of $8.41B, Bruker Corporation is priced for free-cash-flow growth of about 39.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $43.30M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -28.7%/yr over the last five fiscal years and revenue 11.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Bruker Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.